These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38021489)

  • 1. Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification.
    Sinha R; Rana RK; Kujur A; Jahnavi G; Kumar M; Venugopal V; Priya N; Kujur M; Jha RR; Barnwal R; Nishant N; Murmu N; Pathak R; T A; Prasad R; Dayal R; Modi B; Purty AJ; Bn S; Nair D; Kumar D
    Cureus; 2023 Oct; 15(10):e47296. PubMed ID: 38021489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring private sector perspectives on barriers and facilitators in availing tuberculosis care cascade services: a qualitative study from the Indian state.
    Shah HD; Chaudhary S; Desai B; Patel J; Yasobant S; Bhavsar P; Saha S; Sinha AK; Saxena D; Patel Y; Modi B
    BMC Prim Care; 2024 Jan; 25(1):5. PubMed ID: 38166734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative social protection mechanism for alleviating catastrophic expenses on multidrug-resistant tuberculosis patients in Chhattisgarh, India.
    Kundu D; Katre V; Singh K; Deshpande M; Nayak P; Khaparde K; Moitra A; Nair SA; Parmar M
    WHO South East Asia J Public Health; 2015; 4(1):69-77. PubMed ID: 28607277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment delay and out of pocket expenses by notified new tuberculosis patients in an Indian mega city.
    Chadha VK; Praseeja P; Srivastava R; Shivashankar BA; Hemanth Kumar NK; Padmesha R; Suganthi P; Umadevi G; Narayana L; Magesh V; Nagendra N; Puttaswamy G; Jaiswal R; Somashekar N
    Indian J Tuberc; 2022 Oct; 69(4):446-452. PubMed ID: 36460374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis treatment in the private healthcare sector in India: an analysis of recent trends and volumes using drug sales data.
    Arinaminpathy N; Batra D; Maheshwari N; Swaroop K; Sharma L; Sachdeva KS; Khaparde S; Rao R; Gupta D; Vadera B; Nair SA; Rade K; Kumta S; Dewan P
    BMC Infect Dis; 2019 Jun; 19(1):539. PubMed ID: 31217003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisions in TB programme - boon or bane? A qualitative study exploring barriers and facilitators among health care workers in private and public sector, Kerala.
    Mathew G; Kumar SCS; Cherian KM; Issac N; Benjamin AI
    Indian J Tuberc; 2021 Jul; 68(3):356-362. PubMed ID: 34099201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial toxicity of cancer treatment in India: towards closing the cancer care gap.
    Prinja S; Dixit J; Gupta N; Dhankhar A; Kataki AC; Roy PS; Mehra N; Kumar L; Singh A; Malhotra P; Goyal A; Rajsekar K; Krishnamurthy MN; Gupta S
    Front Public Health; 2023; 11():1065737. PubMed ID: 37404274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct out-of-pocket expenditure of tuberculosis treatment in intensive phase in Kalutara District, Sri Lanka.
    Ranawaka N; Nandasena S; De Alwis S
    Indian J Tuberc; 2023 Jul; 70(3):315-318. PubMed ID: 37562906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying costs contributing to catastrophic expenditure among TB patients registered under RNTCP in Delhi metro city in India.
    Sarin R; Vohra V; Singla N; Thomas B; Krishnan R; Muniyandi M
    Indian J Tuberc; 2019 Jan; 66(1):150-157. PubMed ID: 30797274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What would it cost to scale-up private sector engagement efforts for tuberculosis care? Evidence from three pilot programs in India.
    Deo S; Jindal P; Gupta D; Khaparde S; Rade K; Sachdeva KS; Vadera B; Shah D; Patel K; Dave P; Chopra R; Jha N; Papineni S; Vijayan S; Dewan P
    PLoS One; 2019; 14(6):e0214928. PubMed ID: 31166942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of Tuberculosis Care in Programmatic Settings from Karnataka, India: Is It Catastrophic for the Patients?
    Poornima MP; Shruthi MN; Chingale AL; Veena V; Nagaraja SB; Madhukeshwar AK
    Tuberc Res Treat; 2020; 2020():3845694. PubMed ID: 32455013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Market size and sales pattern of tuberculosis drugs in the Philippines.
    Islam T; van Weezenbeek C; Vianzon R; Garfin AM; Hiatt T; Lew WJ; Tisocki K
    Public Health Action; 2013 Dec; 3(4):337-41. PubMed ID: 26393058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of tuberculosis incidence at subnational level using three methods to monitor progress towards ending TB in India, 2015-2020.
    Jeyashree K; Thangaraj J; Rade K; Modi B; Selvaraju S; Velusamy S; Akhil S; Vijayageetha M; Sudha Rani D; Sabarinathan R; Manikandanesan S; Elumalai R; Natarajan M; Joseph B; Mahapatra A; Shamim A; Shah A; Bhardwaj A; Purty A; Vadera B; Sridhar A; Chowdhury A; Shafie A; Choudhury A; Dhrubjyoti D; Solanki H; Sirmanwar K; Khaparde K; Parmar M; Dahiya N; Debdutta P; Ahmed Q; Ramachandran R; Prasad R; Shinde R; Baruah R; Chauhan S; Bharaswadkar S; Achanta S; Sharath BN; Balakrishnan S; Chandra S; Khumukcham S; Mandal S; Chalil S; Shah V; Roddawar V; Rao R; Sachdeva K; Murhekar M;
    BMJ Open; 2022 Jul; 12(7):e060197. PubMed ID: 35902192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs incurred by patients with tuberculosis co-infected with human immunodeficiency virus in Bhavnagar, western India: a sequential explanatory mixed-methods research.
    Rupani MP; Vyas S
    BMC Health Serv Res; 2022 Oct; 22(1):1268. PubMed ID: 36261837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis.
    Getahun B; Wubie M; Dejenu G; Manyazewal T
    Infect Dis Poverty; 2016 Nov; 5(1):93. PubMed ID: 27799063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social franchising of TB care through private GPs in Myanmar: an assessment of treatment results, access, equity and financial protection.
    Lönnroth K; Aung T; Maung W; Kluge H; Uplekar M
    Health Policy Plan; 2007 May; 22(3):156-66. PubMed ID: 17434870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free drug provision for tuberculosis increases patient follow-ups and successful treatment outcomes in the Indian private sector: a quasi experimental study using propensity score matching.
    Sodhi R; Penkunas MJ; Pal A
    BMC Infect Dis; 2023 Jun; 23(1):421. PubMed ID: 37344775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rising healthcare expenditure on tuberculosis: Can India achieve the End TB goal?
    Yadav J; John D; Allarakha S; Menon GR
    Trop Med Int Health; 2021 Oct; 26(10):1256-1275. PubMed ID: 34192385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the influencing factors of out-of-pocket costs on tuberculosis in Sichuan Province: a cross-sectional study.
    Xia L; Gao L; Zhong Y; Wu Y; He J; Zou F; Jian R; Xia S; Chen C; Zhu S
    BMC Public Health; 2023 Jul; 23(1):1391. PubMed ID: 37468877
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.